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ABSTRACT
We summarized the Therapeutic Guidelines for Atopic Dermatitis 2002, and outlined important points with ref-
erence to medical care and management of atopic dermatitis.
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INTRODUCTION
The Therapeutic Guidelines for Atopic Dermatitis
1999 were first announced by the Research Group for
Therapeutic Guideline Construction on Atopic Der-
matitis (Director : Shoso Yamamoto), which was sup-
ported by the Japanese Ministry of Health, Labour
and Welfare. These guidelines were further updated
in 2001 and 2002. They target general physicians .
The structure of these guidelines corresponds with
that of the treatment guidelines proposed by the Japa-
nese Dermatological Association, which are aimed at
dermatologists (http : web .kanazawa-u . ac . jp
med24atopytherapy.html). The classification of the
potency of topical steroids was unified in both guide-
lines．
Although analysis of the pathogenesis and related
genes for atopic dermatitis (AD) is currently pro-
gressing, this work has not yet elucidated the funda-
mental cause of AD. AD is a common, chronic or
chronically relapsing, severely pruritic , eczematous
skin disease. Therefore , the patient’s discomfort is
largely similar to that in other intractable skin dis-
eases. In order to achieve good communication with
patients, it is important for physicians to carefully lis-
ten to how patients describe their discomfort, some-
times over a period of many hours. It is also a pre-
requisite to help patients understand that the medica-
tion currently prescribed is a disease-adapted treat-
ment, although very useful to control disease activity,
and to understand that the majority of patients experi-
ence spontaneous regression during follow-up．
DIAGNOSIS
The symptoms of AD chronically fluctuate with re-
missions and relapses, and many patients have atopic
diathesis. The Japanese Dermatological Association
has established criteria for the diagnosis of AD (Ta-
ble 1).1
PRINCIPLES FOR THERAPY
It is important to treat each patient by appropriately
combining the following three fundamental princi-
ples : (1) elucidation and avoidance of trigger and ag-
gravating factors, (2) skin care, and (3) medication
( Fig . 1). Information about medical treatments
should be explained fully to the patient to create a
good doctor-patient partnership．
GLOBAL CLINICAL SEVERITY
It is necessary to evaluate the global clinical severity
in order to select a suitable treatment. Although sev-
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Definition
Atopic dermatitis is a pruritic, eczematous dermatosis, the symptoms of which chronicaly fluctuate with remissions and 
relapses. Most individuals with atopic dermatitis have atopic diathesis. Atopic diathesis: (1) personal or family history (asth-
ma, alergic rhinitis and/or conjunctivitis, and atopic dermatitis), and/or (2) predisposition to overproduction of immunoglobulin 
E (IgE) antibodies.
Diagnosis
1. Pruritus
2. Typical morphology and distribution:
(1) Eczematous dermatitis 
・Acute lesions: erythema, exudation, papules, 
vesiculopapules, scales and crusts
・Chronic lesions: infiltrated erythema, lichenification, 
prurigo, scales and crusts
(2) Distribution
・Symmetrical
Predilection sites: forehead, periorbital area, pe-
rioral area, lips, periauricular area, neck, joint areas 
of limbs, trunk 
・Age-related characteristics
Infantile phase: starts on the scalp and face, often 
spreads to the trunk and extremities
Childhood phase: neck, the flexural surfaces of the 
arms and legs
Adolescent and adult phase: tendency to be severe 
on the upper half of the body (face, neck, anterior 
chest, and back) 
3. Chronic or chronicaly relapsing course (usualy coexis-
tence of old and new lesions): 
More than two months in infancy
More than six months in childhood, adolescence, 
and adulthood
Definite diagnosis of atopic dermatitis requires the presence 
of al three features without any consideration of severity. 
Other cases should be evaluated on the basis of the clinical 
course with the tentative diagnosis of acute or chronic, non-
specific eczema.
Diferential Diagnosis
・Contact dermatitis
・Seborheic dermatitis
・Prurigo simplex
・Scabies
・Miliaria
・Ichthyosis
・Xerotic eczema
・Hand dermatitis (non-atopic)
Table 1　Definition and Diagnostic Criteria for Atopic Dermatitis by The Japanese Dermatological Association
Diagnostic Aids
・Family history (bronchial asthma, alergic rhinitis and/or 
conjunctivitis, atopic dermatitis)
・Complications (bronchial asthma, alergic rhinitis and/or 
conjunctivitis)
・Folicular papules (goose-skin)
・Elevated serum IgE level
Clinical Types (not applicable to the infantile phase)
・Flexural surface type
・Extensor surface type
・Dry form in childhood
・Head/face/neck/upper chest/back type
・Prurigo type
・Erythroderma type
・Combinations of various types are common
Significant Complications
・Ocular complications (cataracts and/or retinal 
detachment): especialy in patients with severe facial le-
sions
・Kaposi’ svariceliform eruption
・Moluscum contagiosum
・Impetigo contagiosa
eral scoring systems have been reported for the
evaluation of the severity of AD, we herein propose a
simple method considering the affected body surface
areas in order to make it convenient for general phy-
sicians to use (Table 2).
TRIGGER AND AGGRAVATING FACTORS
Because trigger and aggravating factors vary among
patients (Fig. 2), it is necessary to know an individual
patient’s trigger and aggravating factors before rec-
ommending avoidance of any of the known trigger or
aggravating factors for AD.
SKIN CARE
Patients with AD have several functional abnormali-
ties of the skin, such as decreased ability of moisture
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Fig. 1　Principles for therapy
Diagnosis
Evaluation of Severity
Medications
Education and Avoidance of
Trigger and Aggravating Factors 
Skin Care
(compensation for the functional 
abnormalities of the skin)
Fig. 2　Trigger and Aggravating Factors
Because the trigger and aggravating factors vary among patients, it is important to carefully 
elucidate the trigger and aggravating factors before recommending their avoidance.
Infantile
(less than 2 years old)
Childhood
(2 to 12 years old)
Adolescence and Adult
(13 years old and older)
● Foods
● Sweating
● Environmental factors
● Bacteria, fungi
etcetera
● Environmental factors
● Sweating
● Bacteria, fungi
● Contact allergens
● Stress
● Foods
etcetera
：Being covered with mild skin lesions* 
only, irespective of body surface area 
afected 
Mild
：Inflamed skin lesions** covering less 
than 10% of the body surface
Moderate
：Inflamed skin lesions covering more 
than 10% but less than 30% of the 
body surface
Severe
：Inflamed skin lesions covering more 
than 30% of the body surface
Very Severe 
*Mild skin lesions: Dry skin, scaling and faint erythema.
**Inflamed skin lesions: Lesions with erythema, papules, 
erosion, infiltration, lichenification, and so on.
Table 2　Global Clinical Severity
maintenance, decreased threshold of itch sensation
and tendencies toward bacterial and viral infections.
It is known that these abnormalities are strongly re-
lated to the development of symptoms and aggrava-
tion of dermatitis. Suitable skin care is therefore re-
quired to compensate for these abnormalities (Ta-
ble 3).
MEDICATION
Suitable medication is required to control cutaneous
inflammation . Topical steroids and oral anti-
histamineanti-allergic drugs are the mainstay of
treatment of AD. Figure 3 shows fundamental topical
steroid therapy according to severity grading in pa-
tients less than 2 years old, 2 to 12 years old, and 13
years old or older. Table 4 shows a classification of
the potency of topical steroids. The following points
are important for drug treatment. We must select the
potency and vehicle formulation of topical steroids ac-
cording to the patient’s age and distribution and
manifestation of each eruption. We recommend that
general physicians prescribe topical steroids of lower
potency and smaller volume and for as short a period
of time as possible for facial lesions to reduce the oc-
currence of adverse effects . The adverse effects of
topical steroids, such as teleangiectasia and skin atro-
phy, occur more frequently with longer periods of ap-
plication. Physicians must monitor the potency and
dosage of topical steroids for their patients.2 If a pa-
tient suddenly stops the application of topical ster-
oids , the eruptions may exacerbate rapidly . Physi-
cians should ask their patients to tell them when they
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Fig. 3　Fundamental Medication
Mild Moderate Severe Very Severe
Step down
if effective
Topical Drugs
All ages
Non-steroidal topical agents
Topical steroids, if necessary
(lower than mild rank )
 
Oral Drugs
Anti-histamine drugs
Anti-allergic drugs
(If necessary)
Topical Drugs
Less than 2 years old
Topical steroids
(lower than mild rank)
2 to 12 years old
Topical steroids
(lower than strong rank)
13 years old and older
Topical steroids
(lower than very strong rank)
Oral Drugs
Anti-histamine drugs
Anti-allergic drugs
(If necessary)
Topical Drugs
Less than 2 years old
Topical steroids
(lower than strong rank)
2 to 12 years old
Topical steroids
(lower than very strong rank)
13 years old and older
Topical steroids
(lower than very strong rank)
Oral Drugs
Anti-histamine drugs
Anti-allergic drugs
(If necessary)
Oral steroids
(If necessary, temporarily)
Topical Drugs
Less than 2 years old
Topical steroids
(lower than strong rank)
2 to 12 years old
Topical steroids
(lower than very strong rank)
13 years old and older
Topical steroids
(lower than very strong rank)
Oral Drugs
Anti-histamine drugs
Anti-allergic drugs
(If necessary)
Step up
if not effective
● Hospitalization is required 
temporarily
Table 3　Skin Care ( Compensation for the functional abnormalities＊ of the skin)
●
 
Keep the skin clean: bathe and shower daily. 
Remove sweat and dirt promptly; however, do not rub skin strongly.
Avoid soap and shampoo with very potent cleansing power. 
Rinse thoroughly to remove remaining soap and shampoo.
Avoid bathing in very hot water, which can induce pruritus
Avoid using bathing agents that induce a flushing sensation after bathing.
Apply a suitable topical agent after bathing, if necessary.
Physicians should teach the patient or guardian a suitable way to bathe according to the skin condition.
●
 
Moisturizing skin: moisturizing emolients 
Moisturizing emolients are efective protection from dry skin.
Apply moisturizing emolients, if necessary, after taking a bath or shower.
Physicians should prescribe moisturizers according to the patient’ spreference.
Emolients can often improve mild lesions. 
●
 
Miscelaneous points 
Keep the house clean and maintain an appropriate room temperature and humidity
New underwear should be washed before wearing. 
Use detergents containing a lower interfacial activator
Cut the nails short and avoid scratching as much as possible
(Protection with gloves and bandages is often useful) 
Functional abnormalities of the skin: 1) decreased ability of moisture maintenance
2) decreased threshold of itch sensation
3) tendency to bacterial and viral infections
want to change or stop the application of steroids. Ap-
propriate potency and dosage of topical steroids are
necessary to improve acute exacerbations. Emollients
are effective, to some extent, for mild lesions. Oral
anti-histamine and anti-allergic drugs are generally ef-
fective for pruritus in combination with topical ster-
oids and emollients. The clinical severity should be
evaluated after 1 to 2 weeks of treatment to assess
whether the medication should be changed or not．
TOPICAL TACROLIMUS OINTMENT
Topical tacrolimus ointment (a non-steroidal immuno-
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Table 4　Potency of topical steroids
Strongest
0.05% clobetasol propionate
05% diflorasone diacetate
Very strong
0.1% mometasone furoate
0.05% betamethasone butyrate propionate
0.05% fluocinonide
0.064% betamethasone dipropionate
0.05% difluprednate
0.05% budesonide
0.1% amcinonide
0.1% diflucortolone valerate
1% hydrocortisone butyrate propionate
Strong
0.3% deprodone propionate
0.1% dexamethasone propionate
0.12% dexamethasone valerate
0.1% halcinonide
0.12% betamethasone valerate
0.025% beclomethasone dipropionate
025% fluocinolone acetonide
Mild
0.3% prednisolone valerate acetate 
0.1% triamcinolone acetonide
0.02% flumetasone pivalate
0.1% alclometasone dipropionate
0.05% clobetasone butyrate
0.1% hydrocortisone butyrate
1% dexamethasone
Weak
0.5% prednisolone
1% hydrocortisone acetate
modulatory drug or calcineurin inhibitor) is effective,
in particular for facial lesions. Treatment guidelines
for use of topical tacrolimus can be found elsewhere.3
CHECKPOINTS DURING FOLLOW-UP
Over long periods of follow-up, physicians must be
aware of the possibility of various complications and
manage them appropriately. AD is frequently associ-
ated with impetigo contagiosum, Kaposi’s varicelli-
form eruption and molluscum contagiosum. These
complications require early diagnosis and appropriate
treatment. AD is also frequently associated with oph-
thalmic disorders such as cataract and retinal detach-
ment . Repeated rubbing and patting of the orbital
area may be responsible for the exacerbation of oph-
thalmic lesions. Special attention should be paid to
the occurrence of contact dermatitis due to topical
ointments, because the contact dermatitis aggravates
the severity of lesions. These guidelines only outline
the general points of therapeutic management of AD,
and therefore, many additional factors must be con-
sidered in individual cases. Physicians have to con-
sider referring the patients to experts and special
clinics, if good control is not achieved after 1 month
of treatment according to these guidelines．
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